Zhicong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhicong Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bin Xie
School of Pharmacy, Naval Medical University a , Shanghai, 200433, China+020 81871245 +020 81871245
1 shared publication - Peng Fu
Changhai Hospital, Naval Medical University d , Shanghai, 200433, China+020 31162301 +020 31162301
1 shared publication Qianqian Wan
Department of Integrated Chinese and Western Medicine, The Third Affiliated Hospital of Naval Medical University c , Shanghai 200438, China
1 shared publication- Runhui Liu
School of Pharmacy
1 shared publication - Xi-Ke Xu
School of Pharmacy, Naval Medical University, Shanghai 200433, China
1 shared publication Zifan Zhu
School of Pharmacy, Fujian University of Traditional Chinese Medicine b , Fuzhou, 350122, China
1 shared publication
Latest Publications
- 24 May 2023
- Published by Oxford University Press (OUP) in Molecular Omics
- Vol. 19 (8) , 653-667
Integrated network pharmacology and fecal metabolomic analysis of the combinational mechanisms of Shexiang Baoxin Pill against atherosclerosis
Shexiang Baoxin Pill (SBP) has an excellent therapeutic effect on atherosclerosis (AS), but the combinational mechanisms of SBP against AS remain unclear. This study aimed to investigate the combinational mechanisms of SBP against AS by comprehensive network pharmacology and fecal metabolomic analysis. Bufonis venenum, one of the adjuvant medicines in SBP, is an animal medicine with a narrow therapeutic window. Considering animal protection, we evaluated the anti-AS effect of SBP without BV (SBP-BV) using ApoE−/− mouse models, culture cells, and metabolomic methods. Our data suggested that SBP showed remarkable anti-atherosclerotic effects through multiple targets and multiple pathways, while each component in SBP played different roles in their synergistic effect. Notably, SBP-BV showed comparable effects with SBP in the treatment of AS. Both SBP and SBP-BV could reduce cholesterol uptake in RAW264.7 cells and prevent the occurrence and development of AS in WD-induced ApoE−/− mice by attenuating the atherosclerotic plaque area, and reducing inflammatory cytokines and cholesterol levels in vivo. Our finding might provide new insights into the research and development of new anti-atherosclerosis drugs.
- 24 May 2023
- Published by Oxford University Press (OUP) in Molecular Omics
- Vol. 19 (8) , 653-667
Integrated network pharmacology and fecal metabolomic analysis of the combinational mechanisms of Shexiang Baoxin Pill against atherosclerosis
Shexiang Baoxin Pill (SBP) has an excellent therapeutic effect on atherosclerosis (AS), but the combinational mechanisms of SBP against AS remain unclear. This study aimed to investigate the combinational mechanisms of SBP against AS by comprehensive network pharmacology and fecal metabolomic analysis. Bufonis venenum, one of the adjuvant medicines in SBP, is an animal medicine with a narrow therapeutic window. Considering animal protection, we evaluated the anti-AS effect of SBP without BV (SBP-BV) using ApoE−/− mouse models, culture cells, and metabolomic methods. Our data suggested that SBP showed remarkable anti-atherosclerotic effects through multiple targets and multiple pathways, while each component in SBP played different roles in their synergistic effect. Notably, SBP-BV showed comparable effects with SBP in the treatment of AS. Both SBP and SBP-BV could reduce cholesterol uptake in RAW264.7 cells and prevent the occurrence and development of AS in WD-induced ApoE−/− mice by attenuating the atherosclerotic plaque area, and reducing inflammatory cytokines and cholesterol levels in vivo. Our finding might provide new insights into the research and development of new anti-atherosclerosis drugs.